AstraZeneca may have hit rock bottom, but can it rise to new heights?

Back in 2014, Pascal Soriot CEO of AstraZeneca managed to stave off a takeover bid from Pfizer with a bold promise to return the company to growth and achieve revenues of between $41 to $42 billion by 2023. But will the company really be able to double its revenues in less than five years, asks Richard Staines.